.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Platelet-rich plasma is widely used for symptomatic knee osteoarthritis, yet the ideal formulation remains debated. This double-blind randomized trial compared leukocyte-rich PRP with leukocyte-poor PRP in patients with mild-to-moderate knee osteoarthritis who received three weekly injections. Both groups improved over follow-up, but the study did not find a meaningful difference between the two preparations in patient-reported outcomes. This is clinically useful because it suggests that the presence or removal of leukocytes alone may not determine whether PRP improves symptoms. The trial also illustrates why the PRP literature can be difficult to interpret: treatment protocols differ in platelet concentration, leukocyte content, injection number and patient selection, making direct comparisons across studies challenging. For clinicians, the practical lesson is to avoid assuming that one commercially marketed PRP formulation is automatically superior. Patients considering PRP should be counselled that symptom improvement is possible, but the evidence does not establish a single optimal preparation or prove consistent structural disease modification. PRP should therefore be integrated into an overall osteoarthritis treatment plan, with attention to diagnosis, severity, functional goals and the evidence supporting other nonoperative options.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Platelet-rich plasma is widely used for symptomatic knee osteoarthritis, yet the ideal formulation remains debated. This double-blind randomized trial compared leukocyte-rich PRP with leukocyte-poor PRP in patients with mild-to-moderate knee osteoarthritis who received three weekly injections. Both groups improved over follow-up, but the study did not find a meaningful difference between the two preparations in patient-reported outcomes. This is clinically useful because it suggests that the presence or removal of leukocytes alone may not determine whether PRP improves symptoms. The trial also illustrates why the PRP literature can be difficult to interpret: treatment protocols differ in platelet concentration, leukocyte content, injection number and patient selection, making direct comparisons across studies challenging. For clinicians, the practical lesson is to avoid assuming that one commercially marketed PRP formulation is automatically superior. Patients considering PRP should be counselled that symptom improvement is possible, but the evidence does not establish a single optimal preparation or prove consistent structural disease modification. PRP should therefore be integrated into an overall osteoarthritis treatment plan, with attention to diagnosis, severity, functional goals and the evidence supporting other nonoperative options.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
